Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide (Tribenzor)
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide reduces fluid retention and lowers blood pressure by increasing urine output.
Questions a plan sponsor actually asks.
What is Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide used for?
Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide reduces fluid retention and lowers blood pressure by increasing urine output.
Is there a generic for Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide?
No. Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is brand-only with no generic equivalents currently in market.
How much does my plan pay for Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide?
Across 329 Part D plans, Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide averages $2.81/unit (NADAC). Lowest available: $0.866/unit. Highest in distribution: $19.41/unit.
Is Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide on the FDA shortage list?
No. Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (11 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.